Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Conditions: Genetic Predisposition; Paraganglioma; Pheochromocytoma; ALS; Parkinson Disease; Polyneuropathies; Frontotemporal Dementia; Alzheimer Disease; Cardiomyopathy Non-ischemic; Thoracic Aortic Aneurysm Interventions: Behavioral: Behavioral nudge Sponsors: University of Pennsylvania Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
Conditions: Neuroblastoma; Pheochromocytoma; Paraganglioma Interventions: Drug: 18F-mFBG Sponsors: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC); Albert Einstein College of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green
Conditions: Paraganglioma Interventions: Drug: Fluorescence guided identification using indocyanine green Sponsors: Leiden University Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2023 Category: Research Source Type: clinical trials
Trial of Lu-177 DOTATATE (Lutathera ®) in Unlicensed Indications
Conditions: Bronchial and Thymic Neuroendocrine Tumour; Paraganglioma/ Phaeochromocytoma; Medullary Thyroid Carcinoma; Those Requiring Repeat Peptide Receptor Radionuclide Therapy Interventions: Drug: Lu-177 DOTATATE (Lutathera ®) Sponsors: University College, London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
" Receptor Radionuclide Therapy With 177Lu-DOTATOC
Conditions: Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma Intervention: Drug: 177Lu-DOTATOC Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients
Conditions: Pheochromocytoma, Metastatic; Ultrasonography; Paraganglioma, Malignant; Pheochromocytoma Malignant Intervention: Diagnostic Test: Contrast-enhanced ultrasound(CEUS) Sponsor: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
